Clinical Trials

Bavarian Nordic and its partners conduct clinical studies of its vaccine candidates to evaluate their safety and efficacy.

Clinical studies that are actively enrolling patients or are planned are detailed below.


Phase 1/2 Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Location: USA
Read more: NCT02840994


Phase 1/2 Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)
Location: USA
Read more: NCT03493945
An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)
Location: USA
Read more: NCT03349983


Phase 2 Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Location: USA
Read more: NCT03315871
Phase 2 Study of Adjuvant PROSTVAC in Subjects at High Risk for Relapse After Radical Prostatectomy
Location: USA
Read more: NCT02772562
Phase 1/2 Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Location: USA
Read more: NCT02933255
Phase 2 Trial of PROSTVAC and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy
Location: USA
Read more: NCT02506114
Phase 2 Study of PROSTVAC and Docetaxel for Metastatic Castration Sensitive Prostate Cancer
Location: USA
Read more: NCT02649855


Phase 3 study evaluating the safety and immunogenicity of Ebola candidate vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)
Location: Sierra Leone
Read more: NCT02509494